Cases & Deals

Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)

Clients Celgene Corporation

Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®). The patents cover pharmaceutical compositions and formulations comprising such nanoparticles, and medical applications thereof including medical conditions, patient populations, and dosage regimens.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.